ISIS 301012 or Placebo

DRUG3 trials

Sponsors

Kastle Therapeutics, LLC

Conditions

HypercholesterolemiaHypercholesterolemia, Familial

Phase 2

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

CompletedNCT00216463

Kastle Therapeutics, LLCHypercholesterolemia

Start: 2005-08-31End: 2007-08-31Updated: 2016-08-03

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

CompletedNCT00231569

Kastle Therapeutics, LLCHypercholesterolemia

Start: 2005-09-30End: 2007-12-31Updated: 2016-08-03

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

CompletedNCT00281008

Kastle Therapeutics, LLCHypercholesterolemia, Familial

Start: 2006-02-28End: 2007-12-31Updated: 2016-08-03

Related Papers

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

2010-04-01113 citations